Most patients with HER2-positive metastatic breast cancer eventually progress despite treatments, such as the currently approved anti-HER2 ADCs, T-DM1 and T-DXd, and have limited therapeutic options [5, 18]. The gene discussed is ERBB2; the disease is breast cancer.